socalTechnews
Home
Mobile
News and Events
  • Headlines
  • Events
  • Interviews
  • Jobs
  • Directory
  • Members Only
  • Networking
  • Venture Deals
  • Venture Firms
  • Companies
  • About
  • Membership
  • About
  • Contact Us
  • Search News
    Thursday, December 20, 2007

    Valeant Pharmaceutical Sells Rights To Infergen


    Aliso Viejo-based Valeant Pharmaceuticals, a drug development firm developing specialty pharmaceuticals, said Thursday that it has signed a definitive agreement with Three Rivers Pharmaceuticals to sell its U.S. and Canadian rights to the hepatitis C drug Infergen. The deal is worth $91M. The firm said the sale would allow the firm to simplify and focus its operations. Infergen was originally developed by Amgen, which sold the rights to Intermune in 2001, which it subsequently sold it to Valeant in 2005.
    posted on Thursday, December 20, 2007

    Related companies:
    Valeant Pharmaceuticals

    Related stories:
    > Valeant Pharmaceuticals Sells Argentina Ops
    > Valeant Pharmaceuticals Buys Specialty Pharma
    > Valeant Sells European Operations
    > Valeant Pharmaceuticals Makes Cuts
    > Valeant Buys Xcel For $280M

    RSS subscri
be via emailEmail


    Previous news:

    Tuesday, October 14, 2008
    Monday, October 13, 2008
    Friday, October 10, 2008
    Thursday, October 9, 2008
    Wednesday, October 8, 2008